{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:56:53Z","timestamp":1788382613935,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yunnan Province High-Level Talent Training Support Program \"Famous Medical Special Project","award":["No. RLMY20200020"],"award-info":[{"award-number":["No. RLMY20200020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01605-2","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T06:47:51Z","timestamp":1744267671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of glucuronic acid as a biomarker of poor prognosis in acute myeloid leukemia based on plasma metabolomics"],"prefix":"10.1007","volume":"25","author":[{"given":"Jinrong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"1605_CR2","first-page":"1211","volume":"18","author":"NA Long","year":"2022","unstructured":"Long NA, Golla U, Sharma A, Claxton DF. Acute myeloid leukemia stem cells: origin. Charact, Clin Implic. 2022;18:1211\u201326.","journal-title":"Charact, Clin Implic"},{"key":"1605_CR3","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.3390\/curroncol29090491","volume":"29","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins RJ, Francis A, Kuchenbauer F, Sanford D. Management of acute myeloid leukemia: a review for general practitioners in oncology. Curr Oncol (Toronto, Ont). 2022;29:6245\u201359.","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"1605_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502\u201326.","journal-title":"Am J Hematol"},{"issue":"1","key":"1605_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/toxics12010014","volume":"12","author":"B Wu","year":"2023","unstructured":"Wu B, Xu Y, Tang M, Jiang Y, Zhang T, Huang L, et al. A Metabolome and microbiome analysis of acute myeloid leukemia: insights into the carnosine-histidine metabolic pathway. Toxics. 2023;12(1):14.","journal-title":"Toxics."},{"key":"1605_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","volume":"127","author":"EM Stein","year":"2016","unstructured":"Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood. 2016;127:71\u20138.","journal-title":"Blood"},{"key":"1605_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6: e441.","journal-title":"Blood Cancer J"},{"key":"1605_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","volume":"31","author":"M Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Official J Eur Soc Med Oncol. 2020;31:697\u2013712.","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol"},{"key":"1605_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00277-020-04375-x","volume":"100","author":"K Laribi","year":"2021","unstructured":"Laribi K, Sobh M, Ghez D, Baugier de Materre A. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. Ann Hematol. 2021;100:1359\u201376.","journal-title":"Ann Hematol"},{"key":"1605_CR10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/bloodadvances.2022007682","volume":"7","author":"S von Palffy","year":"2023","unstructured":"von Palffy S, Thorsson H, Pe\u00f1a-Mart\u00ednez P, Puente-Moncada N, Sand\u00e9n C, Blom AM, et al. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML. Blood Adv. 2023;7:1204\u201318.","journal-title":"Blood Adv"},{"key":"1605_CR11","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1111\/cas.15855","volume":"114","author":"J Lu","year":"2023","unstructured":"Lu J, Dong Q, Zhang S, Feng Y, Yang J, Zhao L. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6\/JAK2\/STAT3 signaling. Cancer Sci. 2023;114:3287\u2013300.","journal-title":"Cancer Sci"},{"key":"1605_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","volume":"30","author":"J Kim","year":"2019","unstructured":"Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 2019;30:434\u201346.","journal-title":"Cell Metab"},{"issue":"5","key":"1605_CR13","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/biomedicines10051146","volume":"10","author":"E Chiarella","year":"2022","unstructured":"Chiarella E, Nistic\u00f2 C, Di Vito A, Morrone HL, Mesuraca M. Targeting of mevalonate-isoprenoid pathway in acute myeloid leukemia cells by bisphosphonate drugs. Biomedicines. 2022;10(5):1146.","journal-title":"Biomedicines."},{"key":"1605_CR14","doi-asserted-by":"publisher","first-page":"153303382312230","DOI":"10.1177\/15330338231223080","volume":"23","author":"CJ Peng","year":"2024","unstructured":"Peng CJ, Fan Z, Luo JS, Wang LN, Li Y, Liang C, et al. The potential transcriptomic and metabolomic mechanisms of ATO and ATRA in treatment of FLT3-ITD acute myeloid leukemia. Technol Cancer Res Treat. 2024;23:15330338231223080.","journal-title":"Technol Cancer Res Treat"},{"key":"1605_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116065","volume":"228","author":"J Zhao","year":"2024","unstructured":"Zhao J, Wu S, Wang D, Edwards H, Thibodeau J, Kim S, et al. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax. Biochem Pharmacol. 2024;228: 116065.","journal-title":"Biochem Pharmacol"},{"key":"1605_CR16","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","volume":"124","author":"WL Chen","year":"2014","unstructured":"Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL, et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood. 2014;124:1645\u201354.","journal-title":"Blood"},{"key":"1605_CR17","doi-asserted-by":"publisher","first-page":"17017","DOI":"10.1073\/pnas.1315558110","volume":"110","author":"JH Wang","year":"2013","unstructured":"Wang JH, Chen WL, Li JM, Wu SF, Chen TL, Zhu YM, et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci U S A. 2013;110:17017\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1605_CR18","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1038\/s41598-018-23863-9","volume":"8","author":"B Stockard","year":"2018","unstructured":"Stockard B, Garrett T, Guingab-Cagmat J, Meshinchi S, Lamba J. Distinct metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia. Sci Rep. 2018;8:5534.","journal-title":"Sci Rep"},{"key":"1605_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s12185-020-02836-7","volume":"111","author":"X Zhou","year":"2020","unstructured":"Zhou X, Zheng M, Wang Q, Aa J, Cao B, Li J. Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients. Int J Hematol. 2020;111:761\u201370.","journal-title":"Int J Hematol"},{"key":"1605_CR20","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.bbadis.2017.05.012","volume":"1863","author":"TL Wong","year":"2017","unstructured":"Wong TL, Che N, Ma S. Reprogramming of central carbon metabolism in cancer stem cells. Biochim Biophys Acta. 2017;1863:1728\u201338.","journal-title":"Biochim Biophys Acta"},{"key":"1605_CR21","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.210004","volume":"11","author":"KL Magon","year":"2021","unstructured":"Magon KL, Parish JL. From infection to cancer: how DNA tumour viruses alter host cell central carbon and lipid metabolism. Open Biol. 2021;11: 210004.","journal-title":"Open Biol"},{"key":"1605_CR22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/0008-5472.CAN-24-0019","volume":"84","author":"E Bo\u00ebt","year":"2024","unstructured":"Bo\u00ebt E, Sarry JE. Targeting metabolic dependencies fueling the TCA cycle to circumvent therapy resistance in acute myeloid leukemia. Can Res. 2024;84:950\u20132.","journal-title":"Can Res"},{"key":"1605_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-022-01245-z","volume":"15","author":"P Zeng","year":"2022","unstructured":"Zeng P, Lu W, Tian J, Qiao S, Li J, Glorieux C, et al. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy. J Hematol Oncol. 2022;15:30.","journal-title":"J Hematol Oncol"},{"key":"1605_CR24","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-14-1370","volume":"21","author":"HA Zahreddine","year":"2015","unstructured":"Zahreddine HA, Borden KL. Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells. Clin Cancer Res\u202f: an Official J Am Association for Cancer Res. 2015;21:2207\u201310.","journal-title":"Clin Cancer Res : an Official J Am Association for Cancer Res"},{"key":"1605_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature13283","volume":"511","author":"HA Zahreddine","year":"2014","unstructured":"Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 2014;511:90\u20133.","journal-title":"Nature"},{"key":"1605_CR26","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1007\/s13277-015-4428-5","volume":"37","author":"Y Chen","year":"2016","unstructured":"Chen Y, Xu Q, Ji D, Wei Y, Chen H, Li T, et al. Inhibition of pentose phosphate pathway suppresses acute myelogenous leukemia. Tumour Biol\u202f: J Int Soc Oncodev Biol Med. 2016;37:6027\u201334.","journal-title":"Tumour Biol : J Int Soc Oncodev Biol Med"},{"key":"1605_CR27","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood.2023022202","volume":"143","author":"H Gu","year":"2024","unstructured":"Gu H, Chen C, Hou ZS, He XD, Xie S, Ni J, et al. PI3K\u03b3 maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood. 2024;143:1965\u201379.","journal-title":"Blood"},{"key":"1605_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12885-023-10947-7","volume":"23","author":"M Soltani","year":"2023","unstructured":"Soltani M, Ghanadian M, Ghezelbash B, Shokouhi A, Zamyatnin AA Jr, Bazhin AV, et al. PD-L1 stimulation can promote proliferation and survival of leukemic cells by influencing glucose and fatty acid metabolism in acute myeloid leukemia. BMC Cancer. 2023;23:447.","journal-title":"BMC Cancer"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01605-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01605-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01605-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:52:44Z","timestamp":1764917564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01605-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01605-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"111"}}